Natco Pharma Ltd
NSE:NATCOPHARM

Watchlist Manager
Natco Pharma Ltd Logo
Natco Pharma Ltd
NSE:NATCOPHARM
Watchlist
Price: 1 357.6 INR -1.25% Market Closed
Market Cap: 243.2B INR
Have any thoughts about
Natco Pharma Ltd?
Write Note

Natco Pharma Ltd
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Natco Pharma Ltd
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Natco Pharma Ltd
NSE:NATCOPHARM
Total Receivables
â‚ą12B
CAGR 3-Years
41%
CAGR 5-Years
18%
CAGR 10-Years
21%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Total Receivables
â‚ą80.3B
CAGR 3-Years
17%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Total Receivables
â‚ą55.9B
CAGR 3-Years
17%
CAGR 5-Years
7%
CAGR 10-Years
9%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Total Receivables
â‚ą129.9B
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
10%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Total Receivables
â‚ą17.9B
CAGR 3-Years
5%
CAGR 5-Years
3%
CAGR 10-Years
3%
M
Mankind Pharma Ltd
NSE:MANKIND
Total Receivables
â‚ą9.4B
CAGR 3-Years
18%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Natco Pharma Ltd
Glance View

Market Cap
243B INR
Industry
Pharmaceuticals

NATCO Pharma Ltd. engages in the business of pharmaceuticals with research, manufacturing and marketing of finished dosage formulations and active pharmaceutical ingredients. The company is headquartered in Hyderabad, Telangana. The firm is engaged in the development, manufacture and commercialization of complex pharmaceuticals catering to niche therapeutic areas. The firm deals in the production of finished dosage formulations (FDF), which it sells in India, the United States and the Rest of the World, as well as active pharmaceutical ingredients (APIs). Its capabilities include multi-step synthesis, semi-synthetic fusion technologies, production of high-potency APIs and peptides. The firm operates through two segments: pharmaceuticals and agrochemicals. The pharmaceuticals segment, the Company drives its sales through FDFs and APIs. The agrochemicals segment is focused on niche products, including pest management.

NATCOPHARM Intrinsic Value
681.5 INR
Overvaluation 50%
Intrinsic Value
Price

See Also

What is Natco Pharma Ltd's Total Receivables?
Total Receivables
12B INR

Based on the financial report for Jun 30, 2024, Natco Pharma Ltd's Total Receivables amounts to 12B INR.

What is Natco Pharma Ltd's Total Receivables growth rate?
Total Receivables CAGR 10Y
21%

Over the last year, the Total Receivables growth was 38%. The average annual Total Receivables growth rates for Natco Pharma Ltd have been 41% over the past three years , 18% over the past five years , and 21% over the past ten years .

Back to Top